News

Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
October 23, 2020
umitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has been dosed in a Phase 1b/2 study evaluating the oral investigational agent, dubermatinib (TP-0903), an AXL kinase inhibitor, in…
ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program
October 23, 2020
Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address.
CIOctober logo
CIO 2020 October 27th Preview: Oligometastatic Disease and Global Perspectives on Practicing IO During the Pandemic
October 22, 2020
Highlights from the upcoming Tuesday evening CIOctober meeting session, and registration information for the complimentary session on the Clinical and Economic Value of Pushable and Detachable Coils, sponsored by Cook.
Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies
October 21, 2020
LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc.
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
October 21, 2020
Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology
Moleculin Announces Independent Study Validates Annamycin's Ability to Target Lung Localized Tumors
October 21, 2020
Annamycin demonstrated up to 30-fold greater concentration in lungs of Annamycin than the current standard of care drug; enables targeting cancer in its sanctuary site
Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study
October 21, 2020
Adaptive Clinical Trial Platform in Glioblastoma Multiforme, Expected to serve as basis for VAL-083's new drug application (NDA) submission and registration.
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
October 20, 2020
Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating…
CIO Meeting
CIO 2020 October 20th Preview: Case-Based Learning and Morbidity and Mortality
October 16, 2020
Highlights from our next Tuesday evening CIOctober meeting session, and registration information for the complimentary session on Advancing the Clinical Treatment of Bone Metastases.
Precigen's UltraPorator™ Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials
October 15, 2020
Technology transfer of UltraPorator to clinical sites dosing UltraCAR-T successfully completed.
Apexigen's APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer
October 15, 2020
Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug…
Back to Top